CTLA4 and cancer: Overall, our findings indicated that the human anti-CTLA-4 antibody ipilimumab can modulate TA-HEVs when adequately Fc optimized, revealing a promising avenue for the therapeutic modulation of TA-HEVs in patients with cancer.